Loading stock data…
Whitehawk Therapeutics (WHWK)
$4.41+0.25 (+6.01%)
After Hours$4.33-0.08 (-1.81%)· Last close Jun 29
Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Whitehawk Therapeutics, Inc. in the Healthcare sector is trading at $4.41 with a market capitalization of $202M. Wall Street consensus targets $7.20 (5 analysts), implying a +63.3% move over the next 12 months. The stock is currently 20% below its 52-week high of $5.50, remaining 42.7% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +63.3% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0↓ | $7.14M |
| Gross Profit | $0 | $0 | $0 | $0↓ | $6.38M |
| Operating Income | -$23.52M↑ | -$24.89M↓ | -$19.55M↑ | -$54.75M↓ | -$15.22M |
| Net Income | -$22.19M↑ | -$23.25M↓ | -$17.75M↑ | -$52.62M↓ | $73.02M |
Peer Comparison
JNJUNHPFE
Fundamentals
Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. The ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$201.52M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-99.68%
Volume
Today's trading volume
356,405
Recent News
Is Whitehawk Therapeutics (WHWK) One Of The Hot Biotech Stocks Under $5 To Buy?
Whitehawk Therapeutics, Inc. (NASDAQ:WHWK), featuring a year-to-date gain of 71.49% and upside potential of 68.70%, secures a spot on our list of hot biotech stocks under $5 to buy. A busy period of pipeline and platform news has kept the clinical-stage antibody drug conjugate (ADC) company in focus, with fresh data at a major oncology […]
Acuta Capital Sells 56% of Ocular Therapeutix Shares in Q1
Ocular Therapeutix delivers FDA-approved eye therapies and devices, supported by a pipeline targeting multiple ocular diseases.
WHWK Stock Edges Up After Hours: Firm Boosts Pipeline Of Cancer Drugs On The Heels Of Capital Raise
Whitehawk said it has secured rights from Hangzhou DAC to use the CPT113 linker-payload technology in up to five additional internally developed programs.
Acuta Capital Bet on Erasca (ERAS) and Targeted Cancer Treatments With a 354,575 Share Buy
This San Diego biotech develops targeted therapies for RAS/MAPK-driven cancers, advancing several clinical candidates in oncology.
May 2026's Promising Penny Stocks
The market remained flat over the last week but is up 25% over the past year, with earnings forecast to grow by 17% annually. In light of these conditions, identifying stocks with strong financials and clear growth potential becomes crucial for investors seeking value. Although the term "penny stocks" may seem outdated, it still points to smaller or less-established companies that can offer significant opportunities; we've identified three such stocks that stand out for their financial...